OACC vs RXRX vs RLAY vs BEAM vs CRSP

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). Oaktree Acquisition Corp. III Life Sciences (OACC) offers the better valuation at 197. 4x trailing P/E, making it the more compelling value choice. Analysts rate Relay Therapeutics, Inc. (RLAY) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Oaktree Acquisition Corp.

III Life Sciences (OACC) delivered a total return of +7. 0%, compared to -85. 6% for Recursion Pharmaceuticals, Inc. (RXRX). Over 10 years, the gap is even starker: CRSP returned +289. 1% versus RXRX's -81. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Oaktree Acquisition Corp.

III Life Sciences (OACC) is the lower-risk stock at 0. 08β versus Recursion Pharmaceuticals, Inc. 's 2. 99β — meaning RXRX is approximately 3604% more volatile than OACC relative to the S&P 500. On balance sheet safety, Oaktree Acquisition Corp. III Life Sciences (OACC) carries a lower debt/equity ratio of 0% versus 24% for Beam Therapeutics Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to -49. 1% for CRISPR Therapeutics AG. Over a 3-year CAGR, RLAY leads at 123. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Oaktree Acquisition Corp.

III Life Sciences (OACC) is the more profitable company, earning 0. 0% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OACC leads at 0. 0% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Oaktree Acquisition Corp.

III Life Sciences (OACC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 08)). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 2. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OACC: +7. 0%, RXRX: -81. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (OACC (Financial Services) and RXRX (Healthcare) and RLAY (Healthcare) and BEAM (Healthcare) and CRSP (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: OACC is a small-cap quality compounder stock; RXRX is a small-cap high-growth stock; RLAY is a small-cap high-growth stock; BEAM is a small-cap high-growth stock; CRSP is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.